Carotid Intima-media Thickness in Dialysis Patients and Traditional Risk Factors

ConditionsDialysis Patients Hypertension Atherosclerosis

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-70

SponsorMinia University

About this trial

* Cardiovascular disease (CVD) is the leading cause of mortality in hemodialysis (HD) patients. * Carotid intima-media thickness (CIMT) is a validated surrogate marker for atherosclerosis. * Both traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia) and dialysis-specific factors (mineral metabolism disorders, dialysis duration) contribute to vascular damage.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Age 18 or older. 2. Patients with sepsis without AKI at the time of admission.

Disqualifiers

o Active malignancy

Acute infections

Recent cardiovascular events (<3 months)

Poor echocardiographic window for CIMT measurement

Trial population

Renal dialysis patients

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Ultrasound measurements of carotid intima- media thickness
Other intervention
Ultrasound measurements of carotid intima- media thickness

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

• To determine the association between carotid intima - media thickness and: o Hypertension duration o HbA1c o LDL/HDL ratio o Dialysis duration o Parathyroid hormone (PTH) levels

Time frame

6 month

Secondary outcomes

• To compare CIMT between: o Diabetics vs. non-diabetics o Short (<5 yrs) vs. long (≥5 yrs) dialysis duration o Patients with vs. without hyperparathyroidism (PTH >300 pg/m

Time frame

6month

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Minia University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: